Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

Overview of attention for article published in Frontiers in Pharmacology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,070 followers.

RT @FrontPharmacol: New Research: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefop…

07 Jun 2023

Reply Repost Favourite

New Research: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies #pharmacology https://t.co/AcVz9ucbPB

07 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.